Silexion Therapeutics Corp — fact timeline

Silexion Therapeutics Corp: On May 28, 2026, the Company filed a certificate amending its Amended and Restated Memorandum of Association to effect a 1-for-10 reverse share split, increasing par value from $0.0135 to $0.135 per share and reducing issued and outstanding ordinary shares proportionately (effective 2026-05-28).

“On May 28, 2026, the Company’s Board of Directors, acting pursuant to that approval by the Company’s shareholders, effected the Reverse Share Split following the close of trading on the Nasdaq Capital Market through the filing of a certificate with the Companies Registry of the Cayman Islands that served as an effective amendment to the Company’s Amended and Restated Memorandum of Association (the “ Memorandum Amendment ”).”

Silexion Therapeutics Corp reported first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026, was approximately $2.7 million.

“On May 18, 2026, Silexion Therapeutics Corp issued a press release announcing its financial results for the first quarter ended March 31, 2026.”

Silexion Therapeutics Corp entered into Inducement Letter with certain holders valued at approximately $1.0 million (effective 2026-05-15).

“On May 15, 2026, Silexion Therapeutics Corp (“ Silexion ” or the “ Company ”) entered into an inducement offer letter agreement (the “ Inducement Letter ”) with certain holders (each a “ Holder ”) of 1,995,092 of the Company’s existing warrants”

Silexion Therapeutics Corp shareholders approved Reverse share split of the Company's ordinary shares at a ratio of 1-for-10 at the 2026-05-05 meeting.

“The result of the vote on the Reverse Share Split Proposal was as follows : Number of Votes and % of Votes in Favor (Excluding Abstentions) Number of Votes and % of Votes Against (Excluding Abstentions) Abstentions 1,004,667 (61.3%) 633,152 (38.7%) 260”

Silexion Therapeutics Corp shareholders approved Amendment to the Silexion Therapeutics Corp 2024 Equity Incentive Plan to increase the number of ordinary shares added annually under the evergreen provision at the 2026-05-05 meeting.

“The result of the vote on the Evergreen Increase Proposal was as follows: Number of Votes and % of Votes in Favor (Excluding Abstentions) Number of Votes and % of Votes Against (Excluding Abstentions) Abstentions 1,000,423 (61.4%) 629,411 (38.6%) 8,245”

Silexion Therapeutics Corp shareholders approved Increase to the authorized share capital of the Company by 50,000,000 ordinary shares at the 2026-05-05 meeting.

“The result of the vote on the Authorized Share Capital Increase Proposal was as follows: Number of Votes and % of Votes in Favor (Excluding Abstentions) Number of Votes and % of Votes Against (Excluding Abstentions) Abstentions 1,005,128 (61.4%) 632,491 (38.6%) 460”

Silexion Therapeutics Corp: Increase in authorized share capital from $121,500 divided into 9,000,000 ordinary shares to $796,500 divided into 59,000,000 ordinary shares (effective 2026-05-05).

“At the extraordinary general meeting of Silexion Therapeutics Corp (the “ Company ”) originally held on April 28, 2026 and reconvened on May 5, 2026 (the “ Meeting ”), the shareholders of the Company duly approved a resolution serving as an effective amendment to paragraph 5 of the Company’s amended and restated memorandum of association (the “ Memorandum Amendment”) , which increased the Company’s authorized share capital, as described in Item 5.07 below.”

Silexion Therapeutics Corp issued 450,000 ordinary shares of common stock to Moringa Sponsor, LP for $1.8 million of the outstanding amount under the Amended and Restated Promissory Note.

“On September 15, 2025, Silexion Therapeutics Corp, a Cayman Islands exempted company (“ Silexion ” or the “ Company ”) issued 450,000 ordinary shares, par value $0.0135 per share, of Silexion (“ ordinary shares ”), to Moringa Sponsor, LP (the “ Sponsor ”) upon conversion by Silexion of an aggregate of $1.8 million of the outstanding amount under the Amended and Restated Promissory Note, dated August 15, 2024, in an original principal amount of $3.4 million (the “ Sponsor Convertible Note ”), issued by Silexion to the Sponsor.”

Silexion Therapeutics Corp: Increased authorized share capital via amendment to memorandum of association (effective 2025-08-19).

“the shareholders of the Company duly approved a resolution serving as an effective amendment to paragraph 5 of the Company’s amended and restated memorandum of association (the “ Memorandum Amendment”) , which increased the Company's authorized share capital”

Silexion Therapeutics Corp: Filed a certificate with the Cayman Islands Companies Registry to amend the Amended and Restated Memorandum of Association, effecting a 1-for-15 reverse share split. Authorized share capital remains $20,000 but now consists of 1,481,482 ordinary shares; par value increased from $0.0009 to $0.0135 pe (effective 2025-07-28).

“On July 28, 2025, the Company’s Board of Directors, acting pursuant to that approval by the Company’s shareholders, effected the Reverse Share Split following the close of trading on the Nasdaq Capital Market through the filing of a certificate with the Companies Registry of the Cayman Islands that served as an effective amendment to the Company’s Amended and Restated Memorandum of Association (the “ Memorandum Amendment ”).”

Silexion Therapeutics Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“July 18, 2025, Silexion Therapeutics Corp (the “ Company ” or “ Silexion ”) received a letter from the Listing Qualifications Department (the “ Staff ”) of the Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, for the 30 consecutive business days preceding the letter, the closing bid price of the Company’s ordinary shares, par value $0.0009 per share (“ ordinary share s”), was below the minimum $1.00 per share required for continued listing on The Nasdaq Stock Market LLC under Nasdaq Listing Rule 5550(a)(2) (the “ bid price deficiency ”). The Staff indicated in the letter that”

Silexion Therapeutics Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C), 5810(c)(3)(C)).

“Listing Rules 5450(b)(2)(A) and 5450(b)(2)(C), which require a company such as ours whose securities are listed on the Nasdaq Global Market under the “Market Value Standard” to maintain a minimum Market Value of Listed Securities (an “ MVLS ”) of $50,000,000 and a minimum Market Value of Publicly Held Shares (an “ MVPHS ”) of $15,000,000 for continued listing on the Nasdaq Global Market.”

Silexion Therapeutics Corp received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(C)).

“”) , which would remove the Company’s ordinary shares and warrants from listing and registration on Nasdaq. The listing deficiencies, for which we had received two letters from the Nasdaq Listing Qualifications Department on November 19, 2024, relate to our non-compliance with Nasdaq Listing Rules 5450(b)(2)(A) and 5450(b)(2)(C). Those rules require a company such as ours whose securities are listed on the Nasdaq Global Market under the “Market Value Standard” to maintain a minimum Market Value of Listed Securities (an “ MVLS ”) of $50,000,000 and a minimum Market Value of Publicly Held Shar”

Silexion Therapeutics Corp received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A)).

“”) , which would remove the Company’s ordinary shares and warrants from listing and registration on Nasdaq. The listing deficiencies, for which we had received two letters from the Nasdaq Listing Qualifications Department on November 19, 2024, relate to our non-compliance with Nasdaq Listing Rules 5450(b)(2)(A) and 5450(b)(2)(C). Those rules require a company such as ours whose securities are listed on the Nasdaq Global Market under the “Market Value Standard” to maintain a minimum Market Value of Listed Securities (an “ MVLS ”) of $50,000,000 and a minimum Market Value of Publicly Held Shar”

Silexion Therapeutics Corp: Adjusted the terms of outstanding warrants due to a 1-for-9 reverse share split, decreasing the number of shares issuable per warrant and proportionately increasing the exercise price (effective 2024-11-27).

“The Company notified Warrant holders that the Company has made the following adjustments to its outstanding Warrants, effective after the close of trading on November 27, 2024, as to be reflected in the Warrants upon the open of trading on November 29, 2024: • The number of ordinary shares issuable upon the exercise of each pre-Reverse Share Split Warrant to purchase one ordinary share will decrease proportionately to the Reverse Share Split ratio, resulting in each such Warrant being exercisable for 1/9th of an ordinary share following the Reverse Share Split; and • The exercise price of each post-Reverse Share Split Warrant to purchase one whole post-Reverse Share Split ordinary share will be proportionately increased nine-fold (relative to a pre-Reverse Share Split Warrant to purchase one pre-Reverse Share Split ordinary share), to $103.50 per post-Reverse Share Split ordinary share.”

Ilan Shiloah resigned as independent director at Silexion Therapeutics Corp.

“On September 16, 2024, Ilan Shiloah, an independent director serving on the board of directors (the “Board”) of Silexion Therapeutics Corp, a Cayman Islands exempted company (the “Company”), informed the Company that he has resigned from the Board, including from his membership on each of the committees of the Board— the audit committee, the compensation committee, and the corporate governance and nominating committee— effective immediately.”

Silexion Therapeutics Corp underwent a change of control involving Moringa Acquisition Corp, Silexion Therapeutics Ltd. (closed 2024-08-15).

“On August 15, 2024 (the "Closing Date"), Silexion Therapeutics Corp (formerly known as Biomotion Sciences), a Cayman Islands exempted company (the "registrant") consummated the previously announced transactions pursuant to that certain Amended and Restated Business Combination Agreement, dated as of April 3, 2024 (as amended, the "Business Combination Agreement"), by and among the registrant, Moringa Acquisition Corp ("Moringa"), August M.S. Ltd., an Israeli company and a wholly-owned subsidiary of the registrant ("Merger Sub 1"), Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and a wholly-owned subsidiary of the registrant ("Merger Sub 2"), and Silexion Therapeutics Ltd., an Israeli company ("Silexion").”